Anticancer Cellular Immunotherapies: Optimizing the Path from Bench to FDA Approval
A striking number of anticancer cellular immunotherapies, also commonly referred to as adoptive cellular therapies (ACT), are in various...
Joel Sandler's Passles
Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape-Part II
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
Proliferation of Novel Cell Type Platforms in the Oncology Competitive Landscape-Part 1
Perhaps more so than any other modality to date, cancer cell therapies have captured the imaginations and wherewithal of industry,...
Innovation in a Buyer’s Market: Standing out in an Increasingly Crowded and Diversified Cancer Treatment Algorithm (a Cancer Progress contribution)
Imagine being told that you are about to be dropped into a deep and deadly hole with nothing but a grappling hook to pull yourself out....
CD19 and BCMA – “What if This is as Good as it Gets?”
I’m no fortune-teller. But I can predict with a reasonable amount of certainty that, in the next week or so, we’ll see a press...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net